Bionime Corporation (TPE:4737)

Taiwan · Delayed Price · Currency is TWD

56.90

+0.70 (1.25%)

Jun 18, 2026, 1:30 PM CST

-15.66% (1Y)

Market Cap	4.40B +0.7%
Revenue (ttm)	1.76B -9.5%
Net Income	-247.64M
EPS	-3.60
Shares Out	77.29M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	69,619
Open	56.20
Previous Close	56.20
Day's Range	55.50 - 56.90
52-Week Range	49.75 - 73.90
Beta	-0.12
Analysts	Hold
Price Target	72.74 (+27.84%)
Earnings Date	Aug 10, 2026

About Bionime

Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Belarus, Algeria, the United Arab Emirates, Egypt, and internationally. The company manufactures and sells blood glucose meters and test strips to medical equipment companies, pharmacies, and hospitals, as well as offering blood glucose monitoring devices and systems under the RIGHTEST brand; a continuous glucose monitoring system under the iFree CGM brand; and medical blood glucose management systems. It is also involved in the pr... [Read more]

Industry Medical Instruments & Supplies

Sector Healthcare

Founded 2003

Employees 500

Stock Exchange Taiwan Stock Exchange

Ticker Symbol 4737

Full Company Profile

Financial Performance

In 2025, Bionime's revenue was 1.84 billion, a decrease of -4.92% compared to the previous year's 1.93 billion. Losses were -180.28 million, 41.7% more than in 2024.

Financial Statements